Inebilizumab (Uplizna®) for the Treatment of Generalized Myasthenia Gravis (gMG) in Adults
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for inebilizumab (Uplizna) as an add-on to standard therapy for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.